Trinity Biotech PLC (TRIB)
| Market Cap | 94.89M |
| Revenue (ttm) | 90.44M |
| Net Income (ttm) | -28.91M |
| Shares Out | 96.16M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $4.62 |
| Previous Close | $4.54 |
| Change ($) | 0.08 |
| Change (%) | 1.76% |
| Day's Open | 4.57 |
| Day's Range | 4.42 - 4.74 |
| Day's Volume | 271,097 |
| 52-Week Range | 0.62 - 4.77 |
DUBLIN, Ireland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia™ SARS-...
Is Trinity Biotech plc (NASDAQ:TRIB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of to...
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q3 2020 Results - Earnings Call Transcript
DUBLIN, Ireland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory...
Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2020 Results - Earnings Call Transcript
DUBLIN, Ireland, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...
DUBLIN, Ireland, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...
Conference Call Scheduled for August 25, 2020 at 11:00am EASTERN Conference Call Scheduled for August 25, 2020 at 11:00am EASTERN
Trinity Biotech (NASDAQ: TRIB) shares are trading lower on Monday after the company's subsidiary Primus Corp announced it received an FDA warning letter following an inspection of Kansas City ...
DUBLIN, Ireland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...
Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q1 2020 Results - Earnings Call Transcript
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborator...
Trinity Biotech plc's (TRIB) CEO Ronan O'Caoimh on Q4 2019 Results - Earnings Call Transcript
Trinity Biotech PLC (NASDAQ: TRIB) released its fiscal fourth-quarter financial results on Tuesday morning, but that wasn’t what propelled the stock afterward.
Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.
DUBLIN, Ireland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2019 Results - Earnings Call Transcript
DUBLIN, Ireland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...
For more than five years, shares of Trinity Biotech have woefully under-performed peers and the market.
Trinity Biotech PLC (TRIB) CEO Ronan O'Caoimh on Q1 2019 Results - Earnings Call Transcript
About TRIB
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathog... [Read more...]
| Industry Diagnostics & Research | Founded 1992 |
| CEO Ronan O'Caoimh | Employees 579 |
| Stock Exchange NASDAQ | Ticker Symbol TRIB |
Financial Performance
In 2019, TRIB's revenue was $90.44 million, a decrease of -6.80% compared to the previous year's $97.04 million. Losses were -$28.91 million, 30.9% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for TRIB stock is "Strong Buy" and the 12-month stock price forecast is 7.00.